This Is Dividend Stock Johnson & Johnson’s Major Weakness

Although diversification can sometimes be a strength, it can also prove to be a double-edged sword in the long run. Here’s how.

Apr 25, 2014 at 9:30AM

In a previous article on J&J (NYSE:JNJ), I highlighted the company's major strengths -- and it has many, not least of which is its 2.7% dividend yield. Now it's time to focus on its major weakness.

Diversity: A double-edged sword
While J&J's diversity could be seen as a major source of strength for the company, because it provides reduced risk and volatility in the company's sales and profitability, it is not a perfect attribute. By having consumer and medical devices segments in addition to a pharma segment, J&J is less exposed to challenges faced in those divisions; but the company may also miss out on the positive surprises in its segments, too.

Diversification can mean that a company spreads itself too thinly. By this, I mean that it attempts to specialize in a number of areas and business lines; however, it can end up achieving diversification while performing its varied tasks at a sub-optimal level. This can be due to an inefficient allocation of capital. For example, investing too much cash in an underperforming business segment to try and turn it around when the money could be better spent in a different segment that is already highly profitable.

Sector peers
Sector peers, such as Pfizer (NYSE:PFE) and Abbott Laboratories, are attempting to become more specialized than J&J. For instance, pharmaceuticals accounted for 93% of Pfizer's sales in 2013, with the remainder being made up of its consumer health-care segment. Of course, even that specialization still left Pfizer with a revenue decline of 6.5% last year, as compared to J&J's revenue growth of 11%.

While this is only a one-year time period, an increased focus on non-pharma activities does not seem to have hurt J&J in recent years when compared to sector peer Pfizer. However, it raises the question of whether J&J's performance could have been even better were it not for the distraction of less-profitable, but more stable, segments. Indeed, it appears as though Pfizer reached this conclusion and decided to sell off its animal health and nutrition segments in recent years in order to focus time and capital on the most lucrative segment: pharmaceuticals. Could a similar approach from J&J deliver even more profit for shareholders?

Meanwhile, Abbott Laboratories spun-off its research-based pharmaceutical business, AbbVie, on January 1, 2013. In 2013, Abbott Laboratories posted improved sales growth, with the top line increasing by 1.6% compared to 2012. This was higher than the 0.4% sales growth reported in 2012, although clearly the potentially positive effects of the spin-off will take more time to come through. It does, however, show that other companies in the health-care space, such as Abbott Laboratories, are seeking to narrow their specialism in an attempt to stimulate sales and profits.

Looking Ahead
While J&J is currently performing well, as its first quarter update recently showed -- sales up 3.5%, earnings per share up 6.9% versus the first quarter of 2013 -- it could be argued that three separate businesses, as opposed to three segments within the same business, could perform even better, and add even more value for shareholders.

Sure, many investors may argue that a winning formula should not be changed, but if J&J -- or any company -- wants to stay ahead of the competition, it must embrace change and be bold with regard to the changes it makes. Splitting into three distinct entities could maximise profitability, and allow investors in the stock to still access diversification benefits through owning shares in all three entities, while also overcoming what could prove to be J&J's major weakness: spreading itself too thin. 

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That’s beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor’s portfolio. To see our free report on these stocks, just click here now.


Peter Stephens has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information